Anavex Life Sciences Corp. (AVXL)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Anavex Life Sciences Corp. (AVXL)
Company Performance

Current Price

as of Oct 16, 2024

$5.53

P/E Ratio

N/A

Market Cap

$468.5M

Description

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Metrics

Overview

  • HQNew York, NY
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerAVXL
  • Price$5.525+2.50%

Trading Information

  • Market Cap$468.50M
  • Float96.85%
  • Average Daily Volume (1m)573,231
  • Average Daily Volume (3m)835,774
  • EPS-$0.50

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$12.21M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$14.73M
  • EV$217.98M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B3.61
Documents
SEC Filings
8-K (2024-07-30)
8-K (2024-06-21)
8-K (2024-05-09)
8-K (2023-05-24)
8-K (2023-04-14)
8-K (2023-03-13)
8-K (2023-02-07)
10-Q (2024-08-06)
10-Q (2024-05-09)
10-Q (2024-02-07)
10-Q (2023-08-08)
10-Q (2023-05-09)
10-Q (2023-02-07)
10-K (2023-11-27)
Factset Street Account
StreetAccount Earnings Call Q&A Summary: Anavex Life Sciences Q4 ($7.07, 0.00) (2023-11-27T14:33:41Z)
Anavex Life Sciences reports Q4 GAAP EPS ($0.12) vs FactSet ($0.15) [3 est, ($0.16)-(0.13)] ($7.07, 0.00) (2023-11-27T13:02:47Z)
Anavex Life Sciences received agreement from CHMP for submission of marketing authorisation application of oral blarcamesine for Alzheimer's disease ($8.79, 0.00) (2023-12-19T12:33:53Z)
Anavex Life Sciences notes publication demonstrating potential of ANAVEX3-71 to prevent cognitive decline in Alzheimer's disease ($5.13, 0.00) (2023-10-25T12:08:11Z)
Anavex Life Sciences initiates regulatory submission of oral blarcamesine for Alzheimer's disease to European Medicines Agency (EMA) ($6.27, 0.00) (2023-11-20T13:01:29Z)
Anavex Life Sciences announces grant of U.S. patent covering Blarcamesine (ANAVEX2-73) for treatment of insomnia or anxiety ($6.72, 0.00) (2023-11-22T13:05:08Z)
Earnings Calls
Earnings Report 2024Q2
Earnings Report (2023-11-27)
Earnings Report (2023-08-08)